Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 6, 2013, Pages 572-585

  Liberal, Rodrigo ^a,b   Grant, Charlotte R ^a   Sakkas, Lazaros ^c   Bizzaro, Nicola ^d   Bogdanos, Dimitrios P ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b University of Porto   (Portugal)

^c UNIVERSITY OF THESSALY   (Greece)

^d Ospedale San Antonio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOACID DEHYDROGENASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; CHOLESTEROL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERFERON REGULATORY FACTOR 5; MITOCHONDRION ANTIBODY; PYRUVATE DEHYDROGENASE COMPLEX; STAT4 PROTEIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; URSODEOXYCHOLIC ACID;

AFRICAN AMERICAN; ALKALINE PHOSPHATASE BLOOD LEVEL; ANION EXCHANGE; ANTIBODY PRODUCTION; ASIAN; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNE THYROIDITIS; BILE DUCT INJURY; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CROSS REACTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; GASTROINTESTINAL HEMORRHAGE; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; HYPERSPLENISM; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SEX RATIO; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS;

ACA; ALD; ALKALINE PHOSPHATASE; ALP; AMA; ANTI-CENTROMERE ANTIBODY; ANTI-MITOCHONDRIAL ANTIBODY; AUTOIMMUNE LIVER DISEASE; DIFFUSE CUTANEOUS SSC; DSSC; IIFL; INDIRECT IMMUNOFLOURESCENCE; LIMITED CUTANEOUS SSC; LIVER TRANSPLANTATION; LSSC; LT; PBC; PRIMARY BILIARY CIRRHOSIS; SSC; SYSTEMIC SCLEROSIS;

ALGORITHMS; AUTOANTIBODIES; CENTROMERE; HUMANS; IMMUNOLOGIC TECHNIQUES; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA; SCLERODERMA, SYSTEMIC;

EID: 84888435999     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.04.005     Document Type: Review

References (180)

1. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.
2. Rigamonti C., Shand L.M., Feudjo M., Bunn C.C., Black C.M., Denton C.P., et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006, 55:388-394.
3. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
4. Nakamura M., Kondo H., Mori T., Komori A., Matsuyama M., Ito M., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45:118-127.
5. Gershwin M.E., Ansari A.A., Mackay I.R., Nakanuma Y., Nishio A., Rowley M.J., et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000, 174:210-225.
6. Selmi C., Bowlus C.L., Gershwin M.E., Coppel R.L. Primary biliary cirrhosis. Lancet 2011, 377:1600-1609.
7. Hamlyn A.N., Sherlock S. The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. Gut 1974, 15:473-479.
8. Danielsson A., Boqvist L., Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 1990, 11:458-464.
9. Witt-Sullivan H., Heathcote J., Cauch K., Blendis L., Ghent C., Katz A., et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990, 12:98-105.
10. Watson R.G., Angus P.W., Dewar M., Goss B., Sewell R.B., Smallwood R.A. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut 1995, 36:927-930.
11. James O.F., Bhopal R., Howel D., Gray J., Burt A.D., Metcalf J.V. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology 1999, 30:390-394.
12. Kim W.R., Lindor K.D., Locke G.R., Therneau T.M., Homburger H.A., Batts K.P., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
13. Hurlburt K.J., McMahon B.J., Deubner H., Hsu-Trawinski B., Williams J.L., Kowdley K.V. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002, 97:2402-2407.
14. Lazaridis K.N., Talwalkar J.A. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007, 41:494-500.
15. Hohenester S., Oude-Elferink R.P., Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009, 31:283-307.
16. Sood S., Gow P.J., Christie J.M., Angus P.W. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 2004, 127:470-475.
17. Rautiainen H., Salomaa V., Niemela S., Karvonen A.L., Nurmi H., Isoniemi H., et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007, 42:1347-1353.
18. Gershwin M.E., Mackay I.R., Sturgess A., Coppel R.L. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987, 138:3525-3531.
19. Metcalf J.V., Mitchison H.C., Palmer J.M., Jones D.E., Bassendine M.F., James O.F. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
20. Strassburg C.P., Manns M.P. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002, 22:339-352.
21. Courvalin J.C., Worman H.J. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:79-90.
22. Rigopoulou E.I., Davies E.T., Bogdanos D.P., Liaskos C., Mytilinaiou M., Koukoulis G.K., et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007, 27:1226-1231.
23. Worman H.J., Courvalin J.C. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2003, 2:211-217.
24. Liu H., Norman G.L., Shums Z., Worman H.J., Krawitt E.L., Bizzaro N., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010, 35:436-442.
25. Chantran Y., Balloti E., Johanet C. Autoantibodies in primary biliary cirrhosis: Antimitochondrial autoantibodies. Clin Res Hepatol Gastroenterol 2013.
26. Rigamonti C., Bogdanos D.P., Mytilinaiou M.G., Smyk D.S., Rigopoulou E.I., Burroughs A.K. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011, 2011:976427.
27. Mytilinaiou M.G., Meyer W., Scheper T., Rigopoulou E.I., Probst C., Koutsoumpas A.L., et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clin Chim Acta 2012, 413:1211-1216.
28. Johanet C., Beleoken E., Ballot E. Autoantibodies in autoimmune hepatitis: antinuclear antibodies (ANA). Clin Res Hepatol Gastroenterol 2012, 36(4):394-396.
29. Folci M., Meda F., Gershwin M.E., Selmi C. Cutting-edge issues in primary biliary cirrhosis. Clin Rev Allergy Immunol 2012, 42:342-354.
30. You Z., Wang Q., Bian Z., Liu Y., Han X., Peng Y., et al. The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun 2012, 39:216-221.
31. Jones D.E. Pathogenesis of primary biliary cirrhosis. Gut 2007, 56:1615-1624.
32. Tsuda M., Ambrosini Y.M., Zhang W., Yang G.X., Ando Y., Rong G., et al. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology 2011, 54:1293-1302.
33. Rong G., Zhong R., Lleo A., Leung P.S., Bowlus C.L., Yang G.X., et al. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology 2011, 54:196-203.
34. Shimoda S., Miyakawa H., Nakamura M., Ishibashi H., Kikuchi K., Kita H., et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun 2008, 31:110-115.
35. Smyk D.S., Bogdanos D.P., Kriese S., Billinis C., Burroughs A.K., Rigopoulou E.I., et al. Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside. Clin Res Hepatol Gastroenterol 2012, 36(2):110-121.
36. Selmi C., Invernizzi P., Zuin M., Podda M., Gershwin M.E. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005, 25:265-280.
37. Smyk D., Cholongitas E., Kriese S., Rigopoulou E.I., Bogdanos D.P. Primary biliary cirrhosis: family stories. Autoimmune Dis 2011, 2011:189585.
38. Smyk D.S., Rigopoulou E.I., Lleo A., Abeles R.D., Mavropoulos A., Billinis C., et al. Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immun Ageing 2011, 8:12.
39. Bogdanos D.P., Vergani D. Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol 2009, 36:30-39.
40. Lan R.Y., Cheng C., Lian Z.X., Tsuneyama K., Yang G.X., Moritoki Y., et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006, 43:729-737.
41. Lan R.Y., Salunga T.L., Tsuneyama K., Lian Z.X., Yang G.X., Hsu W., et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009, 32:43-51.
42. Bernuzzi F., Fenoglio D., Battaglia F., Fravega M., Gershwin M.E., Indiveri F., et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun 2010, 35:176-180.
43. Prince M.I., Chetwynd A., Craig W.L., Metcalf J.V., James O.F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004, 53:865-870.
44. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52:745-758.
45. Prince M., Chetwynd A., Newman W., Metcalf J.V., James O.F. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28years. Gastroenterology 2002, 123:1044-1051.
46. Milkiewicz P., Heathcote E.J. Fatigue in chronic cholestasis. Gut 2004, 53:475-477.
47. Laurin J.M., DeSotel C.K., Jorgensen R.A., Dickson E.R., Lindor K.D. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 1994, 89:1840-1843.
48. Beuers U., Boberg K.M., Chapman R.W., Chazouilleres O., Invernizzi P., Jones D.E., et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
49. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
50. Lee J., Belanger A., Doucette J.T., Stanca C., Friedman S., Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5:1313-1315.
51. Gong Y., Huang Z., Christensen E., Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007, 102:1799-1807.
52. Reynolds T.B., Denison E.K., Frankl H.D., Lieberman F.L., Peters R.L. Primary biliary cirrhosis with scleroderma. Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med 1971, 50:302-312.
53. Crowe J.P., Christensen E., Butler J., Wheeler P., Doniach D., Keenan J., et al. Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 1980, 78:1437-1441.
54. Selmi C., Meroni P.L., Gershwin M.E. Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis. J Autoimmun 2012, 39:34-42.
55. Coll J., Rives A., Grino M.C., Setoain J., Vivancos J., Balcells A. Prevalence of Sjogren's syndrome in autoimmune diseases. Ann Rheum Dis 1987, 46:286-289.
56. Mang F.W., Michieletti P., O'Rourke K., Cauch-Dudek K., Diamant N., Bookman A., et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 1997, 12:167-170.
57. Parikh-Patel A., Gold E.B., Worman H., Krivy K.E., Gershwin M.E. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001, 33:16-21.
58. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
59. Prince M.I., Ducker S.J., James O.F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010, 59:508-512.
60. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
61. Chighizola C., Shoenfeld Y., Meroni P.L. Systemic sclerosis. Introduction. Autoimmun Rev 2011, 10:239-240.
62. Le Guern V., Mahr A., Mouthon L., Jeanneret D., Carzon M., Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004, 43:1129-1137.
63. Chifflot H., Fautrel B., Sordet C., Chatelus E., Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008, 37:223-235.
64. Mayes M.D., Lacey J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
65. Reveille J.D. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 2003, 5:160-167.
66. Dieude P., Boileau C., Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev 2011, 10:282-290.
67. Grossman C., Dovrish Z., Shoenfeld Y., Amital H. Do infections facilitate the emergence of systemic sclerosis?. Autoimmun Rev 2011, 10:244-247.
68. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 2012, 12:300-304.
69. Nussinovitch U., Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011, 10:259-266.
70. Tamby M.C., Chanseaud Y., Guillevin L., Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003, 2:152-157.
71. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., Platsoucas C.D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
72. Sakkas L.I., Chikanza I.C., Platsoucas C.D. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:679-685.
73. Englert H., Small-McMahon J., Chambers P., O'Connor H., Davis K., Manolios N., et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999, 29:36-41.
74. Hudson M., Rojas-Villarraga A., Coral-Alvarado P., Lopez-Guzman S., Mantilla R.D., Chalem P., et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008, 31:156-159.
75. Mora G.F. Systemic sclerosis: environmental factors. J Rheumatol 2009, 36:2383-2396.
76. Radic M., Martinovic Kaliterna D., Radic J. Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis. Neth J Med 2010, 68:348-353.
77. Arnson Y., Amital H., Guiducci S., Matucci-Cerinic M., Valentini G., Barzilai O., et al. The role of infections in the immunopathogensis of systemic sclerosis-evidence from serological studies. Ann N Y Acad Sci 2009, 1173:627-632.
78. Sherer Y., Cerinic M.M., Bartoli F., Blagojevic J., Conforti M.L., Gilburd B., et al. Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann N Y Acad Sci 2007, 1108:259-267.
79. Antiga E., Quaglino P., Bellandi S., Volpi W., Del Bianco E., Comessatti A., et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010, 162:1056-1063.
80. Fenoglio D., Battaglia F., Parodi A., Stringara S., Negrini S., Panico N., et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011, 139:249-257.
81. Papp G., Horvath I.F., Barath S., Gyimesi E., Sipka S., Szodoray P., et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011, 40:205-210.
82. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
83. Barnett A.J., Miller M., Littlejohn G.O. The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J 1988, 64:121-125.
84. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81:139-153.
85. Meyer O.C., Fertig N., Lucas M., Somogyi N., Medsger T.A. Disease subsets, antinuclear antibody profile, and clinical features in 127French and 247US adult patients with systemic sclerosis. J Rheumatol 2007, 34:104-109.
86. Hunzelmann N., Genth E., Krieg T., Meurer M., Melchers I., Moinzadeh P., et al. [Organ-specific diagnosis in patients with systemic sclerosis: recommendations of the German Network for Systemic Sclerosis (DNSS)]. Z Rheumatol 2008, 67:334-336. [7-40].
87. Vlachoyiannopoulos P.G., Dafni U.G., Pakas I., Spyropoulou-Vlachou M., Stavropoulos-Giokas C., Moutsopoulos H.M. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000, 59:359-367.
88. Penn H., Howie A.J., Kingdon E.J., Bunn C.C., Stratton R.J., Black C.M., et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007, 100:485-494.
89. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
90. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010, 37:42-53.
91. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
92. Murray-Lyon I.M., Thompson R.P., Ansell I.D., Williams R. Scleroderma and primary biliary cirrhosis. Br Med J 1970, 3:258-259.
93. O'Brien S.T., Eddy W.M., Krawitt E.L. Primary biliary cirrhosis associated with scleroderma. Gastroenterology 1972, 62:118-121.
94. Sherlock S., Scheuer P.J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973, 289:674-678.
95. Geffroy Y., Colin R., Hemet J., Galmiche J.P., Guillard J., Hecketsweiler P. [Primary biliary cirrhosis and scleroderma]. Med Chir Dig 1973, 2:281-286.
96. Clarke A.K., Galbraith R.M., Hamilton E.B., Williams R. Rheumatic disorders in primary biliary cirrhosis. Ann Rheum Dis 1978, 37:42-47.
97. Powell F.C., Schroeter A.L., Dickson E.R. Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 1987, 62:75-82.
98. Akimoto S., Ishikawa O., Takagi H., Miyachi Y. Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. J Gastroenterol Hepatol 1998, 13:897-901.
99. Akimoto S., Ishikawa O., Muro Y., Takagi H., Tamura T., Miyachi Y. Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: a comparison with patients with systemic sclerosis alone. J Dermatol 1999, 26:18-22.
100. Marasini B., Gagetta M., Rossi V., Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001, 60:1046-1049.
101. Watt F.E., James O.F., Jones D.E. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004, 97:397-406.
102. Culp K.S., Fleming C.R., Duffy J., Baldus W.P., Dickson E.R. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982, 57:365-370.
103. Modena V., Marengo C., Amoroso A., Rosina F., Costantini P., Bellando P., et al. Primary biliary cirrhosis and rheumatic diseases: a clinical, immunological and immunogenetical study. Clin Exp Rheumatol 1986, 4:129-134.
104. Abraham S., Begum S., Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004, 63:123-129.
105. Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010, 53:162-169.
106. Bartholomew L.G., Cain J.C., Winkelmann R.K., Baggenstoss A.H. Chronic disease of the liver associated with systemic scleroderma. Am J Dig Dis 1964, 9:43-55.
107. Gupta R.C., Seibold J.R., Krishnan M.R., Steigerwald J.C. Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin Exp Immunol 1984, 58:68-76.
108. Chou M.J., Lai M.Y., Lee S.L., Tsay G.J. Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis. J Formos Med Assoc 1992, 91:1075-1080.
109. Gourh P., Agarwal S.K., Divecha D., Assassi S., Paz G., Arora-Singh R.K., et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009, 60:3794-3806.
110. Tuffanelli D.L., Winkelmann R.K. Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961, 84:359-371.
111. D'Angelo W.A., Fries J.F., Masi A.T., Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428-440.
112. Pollak C., Minar E., Dragosics B., Marosi L. [Primary biliary cirrhosis and scleroderma: long-term benign course of a complex autoimmune disease]. Leber Magen Darm 1985, 15:85-89.
113. Stadie V., Wohlrab J., Marsch W.C. [Reynolds syndrome-a rare combination of 2 autoimmune diseases]. Med Klin (Munich) 2002, 97:40-43.
114. Beswick D.R., Klatskin G., Boyer J.L. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology 1985, 89:267-271.
115. Agarwal S.K., Reveille J.D. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010, 22:133-138.
116. Liu X., Invernizzi P., Lu Y., Kosoy R., Bianchi I., Podda M., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010, 42:658-660.
117. Gourh P., Tan F.K., Assassi S., Ahn C.W., McNearney T.A., Fischbach M., et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006, 54:3945-3953.
118. Gourh P., Agarwal S.K., Martin E., Divecha D., Rueda B., Bunting H., et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010, 34:155-162.
119. Sutton I., Neuberger J. Primary biliary cirrhosis: seeking the silent partner of autoimmunity. Gut 2002, 50:743-746.
120. Chung L., Utz P.J. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 2004, 6:156-163.
121. Mytilinaiou M.G., Bogdanos D.P. Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis. Dig Liver Dis 2009, 41:916. [author reply-7].
122. Mitchison H.C., Bassendine M.F., Hendrick A., Bennett M.K., Bird G., Watson A.J., et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?. Hepatology 1986, 6:1279-1284.
123. Caramaschi P., Biasi D., Manzo T., Carletto A., Poli F., Bambara L.M. Anticentromere antibody-clinical associations. A study of 44 patients. Rheumatol Int 1995, 14:253-255.
124. Fussey S.P., Guest J.R., James O.F., Bassendine M.F., Yeaman S.J. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A 1988, 85:8654-8658.
125. Mutimer D.J., Fussey S.P., Yeaman S.J., Kelly P.J., James O.F., Bassendine M.F. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989, 10:403-407.
126. Cha S., Leung P.S., Gershwin M.E., Fletcher M.P., Ansari A.A., Coppel R.L. Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proc Natl Acad Sci U S A 1993, 90:2527-2531.
127. Bogdanos D.P., Baum H., Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003, 7:759-777. [vi].
128. Oertelt S., Rieger R., Selmi C., Invernizzi P., Ansari A.A., Coppel R.L., et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007, 45:659-665.
129. Earnshaw W.C., Machlin P.S., Bordwell B.J., Rothfield N.F., Cleveland D.W. Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. Proc Natl Acad Sci U S A 1987, 84:4979-4983.
130. Fritzler M.J., Rattner J.B., Luft L.M., Edworthy S.M., Casiano C.A., Peebles C., et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011, 10:194-200.
131. Beutner E.H., Krasny S.A., Chorzelski T.P., Rodnan G., Jablonska S., Kumar V. Evaluation of methods for detection of anticentromere antibodies and other antinuclear antibodies. J Am Acad Dermatol 1985, 12:289-295.
132. Rothfield N., Whitaker D., Bordwell B., Weiner E., Senecal J.L., Earnshaw W. Detection of anticentromere antibodies using cloned autoantigen CENP-B. Arthritis Rheum 1987, 30:1416-1419.
133. Tan E.M., Smolen J.S., McDougal J.S., Butcher B.T., Conn D., Dawkins R., et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999, 42:455-464.
134. Moroi Y., Peebles C., Fritzler M.J., Steigerwald J., Tan E.M. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 1980, 77:1627-1631.
135. Tan E.M., Rodnan G.P., Garcia I., Moroi Y., Fritzler M.J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980, 23:617-625.
136. Miyawaki S., Asanuma H., Nishiyama S., Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005, 32:1488-1494.
137. Walker U.A., Tyndall A., Czirjak L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
138. Reveille J.D., Solomon D.H. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412.
139. Reveille J.D., Fischbach M., McNearney T., Friedman A.W., Aguilar M.B., Lisse J., et al. Systemic sclerosis in 3US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332-346.
140. Sato H., Lagan A.L., Alexopoulou C., Vassilakis D.A., Ahmad T., Pantelidis P., et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004, 50:558-564.
141. Kallenberg C.G., Wouda A.A., Hoet M.H., van Venrooij W.J. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six-year follow-up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988, 47:634-641.
142. Mitri G.M., Lucas M., Fertig N., Steen V.D., Medsger T.A. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203-209.
143. Kuwana M., Kaburaki J., Okano Y., Tojo T., Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994, 37:75-83.
144. Hamaguchi Y., Hasegawa M., Fujimoto M., Matsushita T., Komura K., Kaji K., et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008, 158:487-495.
145. Hesselstrand R., Scheja A., Shen G.Q., Wiik A., Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003, 42:534-540.
146. Duncan S.C., Winkelmann R.K. Cancer and scleroderma. Arch Dermatol 1979, 115:950-955.
147. Roumm A.D., Medsger T.A. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 1985, 28:1336-1340.
148. Rosenthal A.K., McLaughlin J.K., Gridley G., Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995, 76:910-914.
149. Higuchi M., Horiuchi T., Ishibashi N., Yoshizawa S., Niho Y., Nagasawa K. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000, 19:123-126.
150. Szekanecz Z., Szekanecz E., Bako G., Shoenfeld Y. Malignancies in autoimmune rheumatic diseases-a mini-review. Gerontology 2011, 57:3-10.
151. Derk C.T., Sakkas L.I., Rasheed M., Artlett C., Jimenez S.A. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003, 30:1994-1996.
152. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
153. Rothfield N.F. Autoantibodies in scleroderma. Rheum Dis Clin North Am 1992, 18:483-498.
154. Hamdouch K., Rodriguez C., Perez-Venegas J., Rodriguez I., Astola A., Ortiz M., et al. Anti-CENPI autoantibodies in scleroderma patients with features of autoimmune liver diseases. Clin Chim Acta 2011, 412:2267-2271.
155. Shoji I., Takagi T., Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med 1992, 31:1348-1355.
156. Powell F.C., Winkelmann R.K., Venencie-Lemarchand F., Spurbeck J.L., Schroeter A.L. The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 1984, 59:700-706.
157. Bernstein R.M., Callender M.E., Neuberger J.M., Hughes G.R., Williams R. Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 1982, 41:612-614.
158. Hansen B.U., Eriksson S., Lindgren S. High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies. Scand J Gastroenterol 1991, 26:707-713.
159. Chan H.L., Lee Y.S., Hong H.S., Kuo T.T. Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 1994, 19:298-302.
160. Whyte J., Hough D., Maddison P.J., McHugh N.J. The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigens. J Autoimmun 1994, 7:413-424.
161. Assassi S., Fritzler M.J., Arnett F.C., Norman G.L., Shah K.R., Gourh P., et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009, 36:2250-2256.
162. Avouac J., Fransen J., Walker U.A., Riccieri V., Smith V., Muller C., et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011, 70:476-481.
163. Fonollosa V., Simeon C.P., Castells L., Garcia F., Castro A., Solans R., et al. Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis. Lupus 2001, 10:628-631.
164. McHugh N.J., James I.E., Fairburn K., Maddison P.J. Autoantibodies to mitochondrial and centromere antigens in primary biliary cirrhosis and systemic sclerosis. Clin Exp Immunol 1990, 81:244-249.
165. Makinen D., Fritzler M., Davis P., Sherlock S. Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983, 26:914-917.
166. Granito A., Muratori P., Muratori L., Pappas G., Cassani F., Worthington J., et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007, 26:831-838.
167. Agmon-Levin N., Shapira Y., Selmi C., Barzilai O., Ram M., Szyper-Kravitz M., et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010, 34:55-58.
168. Stahnke G., Meier E., Scanarini M., Northemann W. Eukaryotic expression of recombinant human centromere autoantigen and its use in a novel ELISA for diagnosis of CREST syndrome. J Autoimmun 1994, 7:107-118.
169. Whyte J., Soriano E., Earnshaw W.C., McHugh N.J. Frequency of autoantibodies to a major epitope on the carboxyl terminal fragment of CENP-B in patients with autoimmune disease. Br J Rheumatol 1995, 34:407-412.
170. Himoto T., Nakai S., Kinekawa F., Yoneyama H., Deguchi A., Kurokochi K., et al. Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody. Dig Dis Sci 2009, 54:360-368.
171. Czaja A.J., Nishioka M., Morshed S.A., Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994, 107:200-207.
172. Parveen S., Morshed S.A., Arima K., Nishioka M., Czaja A.J., Chow W.C., et al. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci 1998, 43:1322-1331.
173. Parveen S., Morshed S.A., Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995, 10:438-445.
174. Yang W.H., Yu J.H., Nakajima A., Neuberg D., Lindor K., Bloch D.B. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2004, 2:1116-1122.
175. Gao L., Tian X., Liu B., Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med 2008, 8:9-15.
176. Ishibashi H., Komori A., Shimoda S., Ambrosini Y.M., Gershwin M.E., Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 2011, 50:1-10.
177. Nakamura M., Komori A., Ito M., Kondo H., Aiba Y., Migita K., et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res 2007, 37(Suppl.3):S412-S419.
178. Nakamura M., Yasunami M., Kondo H., Horie H., Aiba Y., Komori A., et al. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): the HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res 2010, 40:494-504.
179. Aiba Y., Nakamura M., Joshita S., Inamine T., Komori A., Yoshizawa K., et al. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J Gastroenterol 2011, 46:1203-1212.
180. Czaja A.J. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010, 55:2144-2161.